Transdermal estradiol plus oral medroxyprogesterone acetate replacement therapy in primary amenorrheic adolescents. Clinical, hormonal and metabolic aspects
| Autor: | P.N. Adamopoulos, E. Konstantellou, D. Aravantinos, Georgios Creatsas, Nampil Arefetz |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
medicine.medical_specialty
Adolescent medicine.drug_class Medroxyprogesterone Administration Oral Medroxyprogesterone Acetate Administration Cutaneous Gonadal Dysgenesis General Biochemistry Genetics and Molecular Biology Bone remodeling Oral administration Bone Density Internal medicine Hormone replacement therapy (male-to-female) Medicine Medroxyprogesterone acetate Humans Amenorrhea Estradiol business.industry Estrogen Replacement Therapy Obstetrics and Gynecology Glucose Tolerance Test Luteinizing Hormone Lipids Prolactin Endocrinology Estrogen Female medicine.symptom Follicle Stimulating Hormone business medicine.drug Hormone |
| Zdroj: | Maturitas. 18(2) |
| ISSN: | 0378-5122 |
| Popis: | Twelve primary amenorrheic adolescents were treated with transdermal estradiol 100 micrograms (Estraderm TTS-100 (R)) twice weekly for 3 weeks, plus MPA 10 mg per os daily (Provera) for the last 11 days, following an interval of 1 week. A basic examination and a re-examination at 6- and 12-month intervals were carried out for clinical evaluation, hormonal assays, lipid, carbohydrate and bone metabolism. No significant changes were recorded on the FSH, LH, 17 beta-estradiol and PRL serum levels. A significant decrease of TC values and atheromatic indices 1 (TC/HDL) and 2 (LDL/HDL) was seen (P0.05) at the end of treatment. On the other hand a significant increase in apolipoproteins A1 was found. A beneficial effect was also recorded on the bone mass. Finally, no significant side-effects were reported. It is concluded that this kind of hormone replacement therapy is efficient and safe for the treatment of amenorrheic adolescents due to gonadal dysgenesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|